Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.55 USD | -3.61% | +1.99% | -16.84% |
10/05 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
08/05 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.84% | 1.16B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Transcript : Mirum Pharmaceuticals, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-11-2022 01